Example: Heart Attack

Clinical Trials on Leukemia, T-Cell

Total 784 results

NCT00095381

Completed

Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia

Conditions: Leukemia, T-Cell
NCT01626664

Completed

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Conditions: Adult T-cell Leukemia-Lymphoma
NCT00924170

Active, not recruiting

Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

Conditions: Adult T-Cell Leukemia (ATL)
NCT04102150

Active, not recruiting

Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

Conditions: Adult T-cell Leukemia/Lymphoma
NCT01724177

Completed

A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

Conditions: Adult T-Cell Leukemia-Lymphoma
NCT01274533

Completed

Lenalidomide in HTLV-1 Adult T-Cell Leukemia

Conditions: Adult T Cell Leukemia/Lymphoma
NCT00920790

Completed

Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma

Conditions: Adult T-cell Leukemia-lymphoma
NCT00001249

Completed

Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac

Conditions: Leukemia, T-Cell; Lymphoma, T-Cell, Cutaneous
NCT01712659

Recruiting

Ruxolitinib for Adult T-Cell Leukemia

Conditions: T Cell Leukemia, Adult; Leukemia, Adult T-Cell; T Cell Leukemia, HTLV I Associated
NCT00061048

Completed

Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma

Conditions: Acute T-Cell Leukemia-Lymphoma
NCT02737046

Recruiting

Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

Conditions: Adult T-cell Leukemia-Lymphoma; ATLL
NCT01378871

Completed

A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma

Conditions: Adult T Cell Leukemia; Adult T Cell Lymphoma
NCT00145002

Completed

A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)

Conditions: Adult T-cell Leukemia; Lymphoma
NCT01169298

Completed

A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma

Conditions: Adult T-cell Leukemia-Lymphoma; Peripheral T-cell Lymphoma
NCT04301076

Recruiting

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL)

Conditions: Acute Adult T-Cell Leukemia/Lymphoma; Adult T-Cell Leukemia/Lymphoma; Chronic Adult T-Cell Leukemia/Lymphoma; HTLV-1 Infection
NCT03264131

Recruiting

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Conditions: Lymphoma; Adult T-Cell Leukemia/Lymphoma; Lymphatic Diseases
NCT01173887

Completed

Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15

Conditions: Adult T-cell Leukemia-Lymphoma
NCT00001941

Completed

Anti-Tac for Treatment of Leukemia

Conditions: HTLV-I Infection; T Cell Leukemia
NCT01418430

Completed

Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)

Conditions: HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)
NCT02631746

Completed

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

Conditions: Acute Adult T-Cell Leukemia/Lymphoma; Adult T-Cell Leukemia/Lymphoma; Chronic Adult T-Cell Leukemia/Lymphoma; HTLV-1 Infection; Lymphomatous Adult T-Cell Leukemia/Lymphoma; Smoldering Adult T-Cell Leukemia/Lymphoma
NCT01620736

Withdrawn

Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load

Conditions: Human T-cell Leukemia Virus Type 1 Infection
NCT03613428

Not yet recruiting

Ruxolitinib Plus LVP in Patients With R/R ETP-ALL

Conditions: Acute T Cell Leukemia
NCT04264078

Not yet recruiting

Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

Conditions: T-cell Leukemia; T-cell Lymphoma
NCT00117845

Terminated

Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia

Conditions: Leukemia, Adult T-Cell
NCT02689453

Active, not recruiting

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

Conditions: T-Cell Lymphoma Relapsed; Adult T-Cell Leukemia (ATL); Peripheral T-Cell Lymphoma (PTCL); Cutaneous T Cell Lymphoma (CTCL); T-Cell Prolymphocytic Leukemia